CHI3L1 Human siRNA Oligo Duplex (Locus ID 1116)
CAT#: SR319700
CHI3L1 (Human) - 3 unique 27mer siRNA duplexes - 2 nmol each
Need single siRNA in bulk?
Get a free quote
SR319700 is the updated version of SR300798.
CNY 4,090.00
货期*
4周
规格
Cited in 6 publications. |
Product images
经常一起买 (3)
Specifications
Product Data | |
Purity | HPLC purified |
Quality Control | Tested by ESI-MS |
Sequences | Available with shipment |
Stability | One year from date of shipment when stored at -20°C. |
# of transfections | Approximately 330 transfections/2nmol in 24-well plate under optimized conditions (final conc. 10 nM). |
Note | Single siRNA duplex (10nmol) can be ordered. |
Reference Data | |
RefSeq | NM_001276 |
Synonyms | ASRT7; CGP-39; GP-39; GP39; HC-gp39; HCGP-3P; hCGP-39; YK-40; YKL-40; YKL40; YYL-40 |
Components | CHI3L1 (Human) - 3 unique 27mer siRNA duplexes - 2 nmol each (Locus ID 1116)Included - SR30004, Trilencer-27 Universal Scrambled Negative Control siRNA Duplex - 2 nmolIncluded - SR30005, RNAse free siRNA Duplex Resuspension Buffer - 2 ml |
Summary | Chitinases catalyze the hydrolysis of chitin, which is an abundant glycopolymer found in insect exoskeletons and fungal cell walls. The glycoside hydrolase 18 family of chitinases includes eight human family members. This gene encodes a glycoprotein member of the glycosyl hydrolase 18 family. The protein lacks chitinase activity and is secreted by activated macrophages, chondrocytes, neutrophils and synovial cells. The protein is thought to play a role in the process of inflammation and tissue remodeling. [provided by RefSeq, Sep 2009] |
Performance Guranteed | OriGene guarantees that at least two of the three Dicer-Substrate duplexes in the kit will provide at least 70% or more knockdown of the target mRNA when used at 10 nM concentration by quantitative RT-PCR when the TYE-563 fluorescent transfection control duplex (cat# SR30002) indicates that >90% of the cells have been transfected and the HPRT positive control (cat# SR30003) provides 90% knockdown efficiency. For non-conforming siRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the siRNA kit. To arrange for a free replacement with newly designed duplexes, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled siRNA control (quantitative RT-PCR data required). |
Citations (6)
The use of this RNAi has been cited in the following citations: |
---|
A Natural CHI3L1-Targeting Compound, Ebractenoid F, Inhibits Lung Cancer Cell Growth and Migration and Induces Apoptosis by Blocking CHI3L1/AKT Signals.
,null,
Molecules (Basel, Switzerland)
,PubMed ID 36615523
[CHI3L1]
|
Inhibition of Chitinase-3-like-1 by K284-6111 Reduces Atopic Skin Inflammation via Repressing Lactoferrin
,null,
Immune Network
,PubMed ID 34277112
[CHI3L1]
|
Chitinase 3 like 1 (CHI3L1) is a regulator of smooth muscle cell physiology and atherosclerotic lesion stability
,Tsantilas, P;Lao, S;Wu, Z;Eberhard, A;Winski, G;Vaerst, M;Nanda, V;Wang, Y;Kojima, Y;Ye, J;Flores, A;Jarr, KU;Pelisek, J;Eckstein, HH;Matic, L;Hedin, U;Tsao, PS;Paloschi, V;Maegdefessel, L;Leeper, NJ;,
Cardiovascular research
,PubMed ID 33471078
[CHI3L1]
|
Chitinase-3-like-1 deficiency attenuates ethanol-induced liver injury by inhibition of sterol regulatory element binding protein 1-dependent triglyceride synthesis
,Lee, DH;Han, JH;Lee, YS;Jung, YS;Roh, YS;Yun, JS;Han, SB;Hong, JT;,
Metab. Clin. Exp.
,PubMed ID 30935969
[CHI3L1]
|
Suppression of metastasis through inhibition of chitinase 3-like 1 expression by miR-125a-3p-mediated up-regulation of USF1
,Kim, K;Yun, J;Son, D;Kim, J;Jung, J;Choi, J;Kim, Y;Song, J;Kim, S;Kang, S;Shin, D;Roh, Y;Han, S;Hong, J;,
Theranostics
,PubMed ID 30214629
[CHI3L1]
|
Atherosclerosis is exacerbated by chitinase-3-like-1 in amyloid precursor protein transgenic mice
,null,
Theranostics
,PubMed ID 29344304
[CHI3L1]
|
Documents
Product Manuals |
FAQs |
SDS |
Customer
Reviews
Loading...